Next-Generation Sequencing of CYP2C19 in Stent Thrombosis: Implications for Clopidogrel Pharmacogenomics
Purpose Describe CYP2C19 sequencing results in the largest series of clopidogrel-treated cases with stent thrombosis (ST), the closest clinical phenotype to clopidogrel resistance. Evaluate the impact of CYP2C19 genetic variation detected by next-generation sequencing (NGS) with comprehensive annota...
Saved in:
| Published in: | Cardiovascular drugs and therapy Vol. 35; no. 3; pp. 549 - 559 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
New York
Springer US
01.06.2021
Springer Nature B.V |
| Subjects: | |
| ISSN: | 0920-3206, 1573-7241, 1573-7241 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Purpose
Describe
CYP2C19
sequencing results in the largest series of clopidogrel-treated cases with stent thrombosis (ST), the closest clinical phenotype to clopidogrel resistance. Evaluate the impact of
CYP2C19
genetic variation detected by next-generation sequencing (NGS) with comprehensive annotation and functional studies.
Methods
Seventy ST cases on clopidogrel identified from the PLATO trial (
n
= 58) and Mayo Clinic biorepository (
n
= 12) were matched 1:1 with controls for age, race, sex, diabetes mellitus, presentation, and stent type. NGS was performed to cover the entire
CYP2C19
gene. Assessment of exonic variants involved measuring in vitro protein expression levels. Intronic variants were evaluated for potential splicing motif variations.
Results
Poor metabolizers (
n
= 4) and rare
CYP2C19*8
,
CYP2C19*15
, and
CYP2C19*11
alleles were identified only in ST cases.
CYP2C19*17
heterozygote carriers were observed more frequently in cases (
n
= 29) than controls (
n
= 18). Functional studies of
CYP2C19
exonic variants (
n
= 11) revealed 3 cases and only 1 control carrying a deleterious variant as determined by in vitro protein expression studies. Greater intronic variation unique to ST cases (
n
= 169) compared with controls (
n
= 84) was observed with predictions revealing 13 allele candidates that may lead to a potential disruption of splicing and a loss-of-function effect of
CYP2C19
in ST cases.
Conclusion
NGS detected CYP2C19 poor metabolizers and paradoxically greater number of so-called rapid metabolizers in ST cases. Rare deleterious exonic variation occurs in 4%, and potentially disruptive intronic alleles occur in 16% of ST cases. Additional studies are required to evaluate the role of these variants in platelet aggregation and clopidogrel metabolism. |
|---|---|
| AbstractList | PURPOSE: Describe CYP2C19 sequencing results in the largest series of clopidogrel-treated cases with stent thrombosis (ST), the closest clinical phenotype to clopidogrel resistance. Evaluate the impact of CYP2C19 genetic variation detected by next-generation sequencing (NGS) with comprehensive annotation and functional studies.
METHODS: Seventy ST cases on clopidogrel identified from the PLATO trial (n = 58) and Mayo Clinic biorepository (n = 12) were matched 1:1 with controls for age, race, sex, diabetes mellitus, presentation, and stent type. NGS was performed to cover the entire CYP2C19 gene. Assessment of exonic variants involved measuring in vitro protein expression levels. Intronic variants were evaluated for potential splicing motif variations.
RESULTS: Poor metabolizers (n = 4) and rare CYP2C19*8, CYP2C19*15, and CYP2C19*11 alleles were identified only in ST cases. CYP2C19*17 heterozygote carriers were observed more frequently in cases (n = 29) than controls (n = 18). Functional studies of CYP2C19 exonic variants (n = 11) revealed 3 cases and only 1 control carrying a deleterious variant as determined by in vitro protein expression studies. Greater intronic variation unique to ST cases (n = 169) compared with controls (n = 84) was observed with predictions revealing 13 allele candidates that may lead to a potential disruption of splicing and a loss-of-function effect of CYP2C19 in ST cases.
CONCLUSION: NGS detected CYP2C19 poor metabolizers and paradoxically greater number of so-called rapid metabolizers in ST cases. Rare deleterious exonic variation occurs in 4%, and potentially disruptive intronic alleles occur in 16% of ST cases. Additional studies are required to evaluate the role of these variants in platelet aggregation and clopidogrel metabolism. Describe CYP2C19 sequencing results in the largest series of clopidogrel-treated cases with stent thrombosis (ST), the closest clinical phenotype to clopidogrel resistance. Evaluate the impact of CYP2C19 genetic variation detected by next-generation sequencing (NGS) with comprehensive annotation and functional studies. Seventy ST cases on clopidogrel identified from the PLATO trial (n = 58) and Mayo Clinic biorepository (n = 12) were matched 1:1 with controls for age, race, sex, diabetes mellitus, presentation, and stent type. NGS was performed to cover the entire CYP2C19 gene. Assessment of exonic variants involved measuring in vitro protein expression levels. Intronic variants were evaluated for potential splicing motif variations. Poor metabolizers (n = 4) and rare CYP2C19*8, CYP2C19*15, and CYP2C19*11 alleles were identified only in ST cases. CYP2C19*17 heterozygote carriers were observed more frequently in cases (n = 29) than controls (n = 18). Functional studies of CYP2C19 exonic variants (n = 11) revealed 3 cases and only 1 control carrying a deleterious variant as determined by in vitro protein expression studies. Greater intronic variation unique to ST cases (n = 169) compared with controls (n = 84) was observed with predictions revealing 13 allele candidates that may lead to a potential disruption of splicing and a loss-of-function effect of CYP2C19 in ST cases. NGS detected CYP2C19 poor metabolizers and paradoxically greater number of so-called rapid metabolizers in ST cases. Rare deleterious exonic variation occurs in 4%, and potentially disruptive intronic alleles occur in 16% of ST cases. Additional studies are required to evaluate the role of these variants in platelet aggregation and clopidogrel metabolism. Describe CYP2C19 sequencing results in the largest series of clopidogrel-treated cases with stent thrombosis (ST), the closest clinical phenotype to clopidogrel resistance. Evaluate the impact of CYP2C19 genetic variation detected by next-generation sequencing (NGS) with comprehensive annotation and functional studies.PURPOSEDescribe CYP2C19 sequencing results in the largest series of clopidogrel-treated cases with stent thrombosis (ST), the closest clinical phenotype to clopidogrel resistance. Evaluate the impact of CYP2C19 genetic variation detected by next-generation sequencing (NGS) with comprehensive annotation and functional studies.Seventy ST cases on clopidogrel identified from the PLATO trial (n = 58) and Mayo Clinic biorepository (n = 12) were matched 1:1 with controls for age, race, sex, diabetes mellitus, presentation, and stent type. NGS was performed to cover the entire CYP2C19 gene. Assessment of exonic variants involved measuring in vitro protein expression levels. Intronic variants were evaluated for potential splicing motif variations.METHODSSeventy ST cases on clopidogrel identified from the PLATO trial (n = 58) and Mayo Clinic biorepository (n = 12) were matched 1:1 with controls for age, race, sex, diabetes mellitus, presentation, and stent type. NGS was performed to cover the entire CYP2C19 gene. Assessment of exonic variants involved measuring in vitro protein expression levels. Intronic variants were evaluated for potential splicing motif variations.Poor metabolizers (n = 4) and rare CYP2C19*8, CYP2C19*15, and CYP2C19*11 alleles were identified only in ST cases. CYP2C19*17 heterozygote carriers were observed more frequently in cases (n = 29) than controls (n = 18). Functional studies of CYP2C19 exonic variants (n = 11) revealed 3 cases and only 1 control carrying a deleterious variant as determined by in vitro protein expression studies. Greater intronic variation unique to ST cases (n = 169) compared with controls (n = 84) was observed with predictions revealing 13 allele candidates that may lead to a potential disruption of splicing and a loss-of-function effect of CYP2C19 in ST cases.RESULTSPoor metabolizers (n = 4) and rare CYP2C19*8, CYP2C19*15, and CYP2C19*11 alleles were identified only in ST cases. CYP2C19*17 heterozygote carriers were observed more frequently in cases (n = 29) than controls (n = 18). Functional studies of CYP2C19 exonic variants (n = 11) revealed 3 cases and only 1 control carrying a deleterious variant as determined by in vitro protein expression studies. Greater intronic variation unique to ST cases (n = 169) compared with controls (n = 84) was observed with predictions revealing 13 allele candidates that may lead to a potential disruption of splicing and a loss-of-function effect of CYP2C19 in ST cases.NGS detected CYP2C19 poor metabolizers and paradoxically greater number of so-called rapid metabolizers in ST cases. Rare deleterious exonic variation occurs in 4%, and potentially disruptive intronic alleles occur in 16% of ST cases. Additional studies are required to evaluate the role of these variants in platelet aggregation and clopidogrel metabolism.CONCLUSIONNGS detected CYP2C19 poor metabolizers and paradoxically greater number of so-called rapid metabolizers in ST cases. Rare deleterious exonic variation occurs in 4%, and potentially disruptive intronic alleles occur in 16% of ST cases. Additional studies are required to evaluate the role of these variants in platelet aggregation and clopidogrel metabolism. Purpose Describe CYP2C19 sequencing results in the largest series of clopidogrel-treated cases with stent thrombosis (ST), the closest clinical phenotype to clopidogrel resistance. Evaluate the impact of CYP2C19 genetic variation detected by next-generation sequencing (NGS) with comprehensive annotation and functional studies. Methods Seventy ST cases on clopidogrel identified from the PLATO trial ( n = 58) and Mayo Clinic biorepository ( n = 12) were matched 1:1 with controls for age, race, sex, diabetes mellitus, presentation, and stent type. NGS was performed to cover the entire CYP2C19 gene. Assessment of exonic variants involved measuring in vitro protein expression levels. Intronic variants were evaluated for potential splicing motif variations. Results Poor metabolizers ( n = 4) and rare CYP2C19*8 , CYP2C19*15 , and CYP2C19*11 alleles were identified only in ST cases. CYP2C19*17 heterozygote carriers were observed more frequently in cases ( n = 29) than controls ( n = 18). Functional studies of CYP2C19 exonic variants ( n = 11) revealed 3 cases and only 1 control carrying a deleterious variant as determined by in vitro protein expression studies. Greater intronic variation unique to ST cases ( n = 169) compared with controls ( n = 84) was observed with predictions revealing 13 allele candidates that may lead to a potential disruption of splicing and a loss-of-function effect of CYP2C19 in ST cases. Conclusion NGS detected CYP2C19 poor metabolizers and paradoxically greater number of so-called rapid metabolizers in ST cases. Rare deleterious exonic variation occurs in 4%, and potentially disruptive intronic alleles occur in 16% of ST cases. Additional studies are required to evaluate the role of these variants in platelet aggregation and clopidogrel metabolism. PurposeDescribe CYP2C19 sequencing results in the largest series of clopidogrel-treated cases with stent thrombosis (ST), the closest clinical phenotype to clopidogrel resistance. Evaluate the impact of CYP2C19 genetic variation detected by next-generation sequencing (NGS) with comprehensive annotation and functional studies.MethodsSeventy ST cases on clopidogrel identified from the PLATO trial (n = 58) and Mayo Clinic biorepository (n = 12) were matched 1:1 with controls for age, race, sex, diabetes mellitus, presentation, and stent type. NGS was performed to cover the entire CYP2C19 gene. Assessment of exonic variants involved measuring in vitro protein expression levels. Intronic variants were evaluated for potential splicing motif variations.ResultsPoor metabolizers (n = 4) and rare CYP2C19*8, CYP2C19*15, and CYP2C19*11 alleles were identified only in ST cases. CYP2C19*17 heterozygote carriers were observed more frequently in cases (n = 29) than controls (n = 18). Functional studies of CYP2C19 exonic variants (n = 11) revealed 3 cases and only 1 control carrying a deleterious variant as determined by in vitro protein expression studies. Greater intronic variation unique to ST cases (n = 169) compared with controls (n = 84) was observed with predictions revealing 13 allele candidates that may lead to a potential disruption of splicing and a loss-of-function effect of CYP2C19 in ST cases.ConclusionNGS detected CYP2C19 poor metabolizers and paradoxically greater number of so-called rapid metabolizers in ST cases. Rare deleterious exonic variation occurs in 4%, and potentially disruptive intronic alleles occur in 16% of ST cases. Additional studies are required to evaluate the role of these variants in platelet aggregation and clopidogrel metabolism. |
| Author | Zhang, Lingxin Klee, Eric W. Storey, Robert F. Jenkins, Gregory D. Wang, Liewei Weinshilboum, Richard Goel, Kashish Roger, Veronique L. Rihal, Charanjit S. Eckloff, Bruce W. Eriksson, Niclas Sicotte, Hugues Baheti, Saurabh James, Stefan Bielinski, Suzette J. Wallentin, Lars Goodman, Shaun G. Morales-Rosado, Joel A. Åkerblom, Axel Black, John L. Johnson, Stephen Pereira, Naveen L. |
| AuthorAffiliation | 1 Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA 3 Vanderbilt University School of Medicine, Nashville, TN 37215, USA 7 Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK 10 Medical Genome Facility, Mayo Clinic, Rochester, MN, USA 12 Department of Cardiovascular Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA 11 Division of Epidemiology, Mayo Clinic, Department of Health Sciences Research, Rochester, MN, USA 6 Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA 2 Center for Individualized Medicine, Mayo Clinic, Rochester, MN, USA 8 St. Michael’s Hospital, University of Toronto, Toronto, Canada 9 Canadian VIGOUR Centre, University of Alberta, Edmonton, Canada 4 Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA 5 Department of Medical Sciences, Cardiology and Uppsala Clinical Rese |
| AuthorAffiliation_xml | – name: 6 Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA – name: 11 Division of Epidemiology, Mayo Clinic, Department of Health Sciences Research, Rochester, MN, USA – name: 10 Medical Genome Facility, Mayo Clinic, Rochester, MN, USA – name: 1 Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA – name: 5 Department of Medical Sciences, Cardiology and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden – name: 9 Canadian VIGOUR Centre, University of Alberta, Edmonton, Canada – name: 4 Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA – name: 8 St. Michael’s Hospital, University of Toronto, Toronto, Canada – name: 3 Vanderbilt University School of Medicine, Nashville, TN 37215, USA – name: 12 Department of Cardiovascular Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA – name: 2 Center for Individualized Medicine, Mayo Clinic, Rochester, MN, USA – name: 7 Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK |
| Author_xml | – sequence: 1 givenname: Joel A. surname: Morales-Rosado fullname: Morales-Rosado, Joel A. organization: Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Center for Individualized Medicine, Mayo Clinic – sequence: 2 givenname: Kashish surname: Goel fullname: Goel, Kashish organization: Vanderbilt University School of Medicine – sequence: 3 givenname: Lingxin surname: Zhang fullname: Zhang, Lingxin organization: Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic – sequence: 4 givenname: Axel surname: Åkerblom fullname: Åkerblom, Axel organization: Department of Medical Sciences, Cardiology and Uppsala Clinical Research Center, Uppsala University – sequence: 5 givenname: Saurabh surname: Baheti fullname: Baheti, Saurabh organization: Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic – sequence: 6 givenname: John L. surname: Black fullname: Black, John L. organization: Department of Laboratory Medicine and Pathology, Mayo Clinic – sequence: 7 givenname: Niclas surname: Eriksson fullname: Eriksson, Niclas organization: Department of Medical Sciences, Cardiology and Uppsala Clinical Research Center, Uppsala University – sequence: 8 givenname: Lars surname: Wallentin fullname: Wallentin, Lars organization: Department of Medical Sciences, Cardiology and Uppsala Clinical Research Center, Uppsala University – sequence: 9 givenname: Stefan surname: James fullname: James, Stefan organization: Department of Medical Sciences, Cardiology and Uppsala Clinical Research Center, Uppsala University – sequence: 10 givenname: Robert F. surname: Storey fullname: Storey, Robert F. organization: Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield – sequence: 11 givenname: Shaun G. surname: Goodman fullname: Goodman, Shaun G. organization: St. Michael’s Hospital, University of Toronto, Canadian VIGOUR Centre, University of Alberta – sequence: 12 givenname: Gregory D. surname: Jenkins fullname: Jenkins, Gregory D. organization: Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic – sequence: 13 givenname: Bruce W. surname: Eckloff fullname: Eckloff, Bruce W. organization: Medical Genome Facility, Mayo Clinic – sequence: 14 givenname: Suzette J. surname: Bielinski fullname: Bielinski, Suzette J. organization: Division of Epidemiology, Mayo Clinic, Department of Health Sciences Research – sequence: 15 givenname: Hugues surname: Sicotte fullname: Sicotte, Hugues organization: Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic – sequence: 16 givenname: Stephen surname: Johnson fullname: Johnson, Stephen organization: Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic – sequence: 17 givenname: Veronique L. surname: Roger fullname: Roger, Veronique L. organization: Department of Cardiovascular Medicine, Mayo Clinic – sequence: 18 givenname: Liewei surname: Wang fullname: Wang, Liewei organization: Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic – sequence: 19 givenname: Richard surname: Weinshilboum fullname: Weinshilboum, Richard organization: Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic – sequence: 20 givenname: Eric W. surname: Klee fullname: Klee, Eric W. organization: Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Center for Individualized Medicine, Mayo Clinic – sequence: 21 givenname: Charanjit S. surname: Rihal fullname: Rihal, Charanjit S. organization: Department of Cardiovascular Medicine, Mayo Clinic – sequence: 22 givenname: Naveen L. orcidid: 0000-0003-3813-3469 surname: Pereira fullname: Pereira, Naveen L. email: pereira.naveen@mayo.edu organization: Department of Cardiovascular Medicine, Mayo Clinic |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32623598$$D View this record in MEDLINE/PubMed https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-430806$$DView record from Swedish Publication Index (Uppsala universitet) |
| BookMark | eNp9ks1u1DAUhS1URKeFF2CBIrFhQcD_jllUqgYolSqoREFiZdmOk3GV2IOdMPD2mJkp0C668uJ-5-j43nMEDkIMDoCnCL5CEIrXGUHGRA0xrCGXTVNvHoAFYoLUAlN0ABZQlhHBkB-Co5yvYRFJ2TwChwRzTJhsFmD10f2c6jMXXNKTj6H67L7PLlgf-ip21fLbJV4iWfkymFyYqqtViqOJ2ec31fm4HrzdynLVxVQth7j2beyTG6rLlU6jtrF3IY7e5sfgYaeH7J7s32Pw5f27q-WH-uLT2fny9KK2DKGpbmUnDCWUGIgFF5y1TLCm64xBTcsJMVYyyqSRXcsohoZqKaDQQmMmHGkNOQYvd75549azUevkR51-qai9euu_nqqYejXPihLYQF7wkx1e2NG1tvwx6eGW6vYk-JXq4w8lhJCc02LwYm-QYtlcntTos3XDoIOLc1a4pOSUEi4K-vwOeh3nFMo2FGYYS04FlIV69n-iv1FublaAZgfYFHNOrlPWT9srlIB-UAiqP_VQu3qoUg-1rYfaFCm-I71xv1dE9hstcOhd-hf7HtVvflfONA |
| CitedBy_id | crossref_primary_10_3390_jpm11050400 crossref_primary_10_1146_annurev_pharmtox_051921_092701 crossref_primary_10_2217_pgs_2021_0058 crossref_primary_10_3389_fphar_2023_1286764 crossref_primary_10_3390_jpm11111226 crossref_primary_10_1186_s40360_024_00750_w crossref_primary_10_1016_j_bios_2022_114138 |
| Cites_doi | 10.3390/jpm8010008 10.1038/clpt.2013.105 10.1161/CIRCINTERVENTIONS.119.007811 10.1101/gr.182899.114 10.1111/1440-1681.12297 10.1124/dmd.115.064428 10.1016/j.jacc.2010.05.013 10.1016/j.mayocp.2015.04.011 10.1038/ng.806 10.1016/j.mayocp.2013.06.006 10.1002/0471250953.bi1110s43 10.1056/NEJMoa0809171 10.1038/nrcardio.2015.64 10.1089/1066527041410418 10.1161/CIRCULATIONAHA.107.707331 10.1001/jama.2011.1529 10.1016/S0140-6736(10)61274-3 10.1186/s13059-019-1847-4 10.1016/j.jcin.2008.09.008 10.1016/j.molcel.2015.05.035 10.1124/dmd.118.084269 10.5808/GI.2015.13.4.112 10.1038/s41588-018-0122-z 10.1093/nar/29.5.1185 10.1161/JAHA.117.005958 10.1161/CIRCULATIONAHA.109.885194 10.1093/nar/15.17.7155 10.1016/j.ajhg.2011.07.014 10.1001/jama.2009.1232 10.1093/nar/gkp215 10.1074/jbc.REV118.002814 10.1056/NEJMoa0808227 10.1038/tpj.2014.30 10.1093/nar/gkx183 10.1089/cmb.1997.4.311 10.1001/jama.2014.14601 10.1101/gr.107524.110 10.1101/gr.137323.112 10.1093/hmg/7.5.919 10.1001/jama.2010.1543 10.1093/ije/dys195 10.1097/00008571-200212000-00004 10.1161/JAHA.115.002490 10.1038/nmeth.4029 10.1016/j.ahj.2010.12.011 10.1124/dmd.110.037549 10.1161/CIRCGENETICS.115.001318 |
| ContentType | Journal Article |
| Copyright | Springer Science+Business Media, LLC, part of Springer Nature 2020 Springer Science+Business Media, LLC, part of Springer Nature 2020. |
| Copyright_xml | – notice: Springer Science+Business Media, LLC, part of Springer Nature 2020 – notice: Springer Science+Business Media, LLC, part of Springer Nature 2020. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88E 8AO 8FD 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FR3 FYUFA GHDGH K9. M0S M1P M7Z P64 PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM ACNBI ADTPV AOWAS D8T DF2 ZZAVC |
| DOI | 10.1007/s10557-020-06988-w |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Technology Research Database ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central ProQuest One Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database Biochemistry Abstracts 1 Biotechnology and BioEngineering Abstracts Proquest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) SWEPUB Uppsala universitet full text SwePub SwePub Articles SWEPUB Freely available online SWEPUB Uppsala universitet SwePub Articles full text |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Technology Research Database ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Biochemistry Abstracts 1 Engineering Research Database ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic Technology Research Database |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1573-7241 |
| EndPage | 559 |
| ExternalDocumentID | oai_DiVA_org_uu_430806 PMC7779664 32623598 10_1007_s10557_020_06988_w |
| Genre | Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: National Heart, Lung, and Blood Institute grantid: U01 HL128606 funderid: http://dx.doi.org/10.13039/100000050 – fundername: NHLBI NIH HHS grantid: U01 HL128606 |
| GroupedDBID | --- -53 -5E -5G -BR -EM -Y2 -~C .86 .GJ .VR 06C 06D 0R~ 0VY 1N0 1SB 2.D 203 28- 29B 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2VQ 2~H 30V 3V. 4.4 406 408 409 40D 40E 53G 5GY 5QI 5RE 5VS 67Z 6NX 7X7 88E 8AO 8FI 8FJ 8FW 8UJ 95- 95. 95~ 96X AAAVM AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AAKAS AANXM AANZL AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAYIU AAYQN AAYTO AAYZH ABAKF ABBBX ABBXA ABDZT ABECU ABFTV ABHLI ABHQN ABIPD ABJNI ABJOX ABKCH ABKTR ABMNI ABMQK ABNWP ABPLI ABQBU ABQSL ABSXP ABTEG ABTKH ABTMW ABULA ABUWG ABWNU ABXPI ACAOD ACBXY ACDTI ACGFS ACHSB ACHXU ACIWK ACKNC ACMDZ ACMLO ACOKC ACOMO ACPIV ACPRK ACUDM ACZOJ ADBBV ADHHG ADHIR ADIMF ADINQ ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADZCM ADZKW AEBTG AEFIE AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFEXP AFKRA AFLOW AFQWF AFRAH AFWTZ AFZKB AGAYW AGDGC AGGDS AGJBK AGMZJ AGQEE AGQMX AGRTI AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHMBA AHSBF AHYZX AIAKS AIGIU AIIXL AILAN AITGF AJBLW AJRNO AJZVZ AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG AVWKF AXYYD AZFZN B-. BA0 BBWZM BDATZ BENPR BGNMA BPHCQ BSONS BVXVI CAG CCPQU COF CS3 CSCUP DDRTE DL5 DNIVK DPUIP DU5 EBD EBLON EBS EIOEI EJD EMOBN EN4 ESBYG F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GQ8 GRRUI GXS H13 HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ I09 IHE IJ- IKXTQ IMOTQ ITM IWAJR IXC IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV KOW KPH L7B LAK LLZTM LSO M1P M4Y MA- N2Q NB0 NDZJH NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM OVD P19 P2P P9S PF0 PQQKQ PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS R4E R89 R9I RHV RNI ROL RPX RRX RSV RZC RZE RZK S16 S1Z S26 S27 S28 S37 S3B SAP SCLPG SDE SDH SDM SHX SISQX SJYHP SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZ9 SZN T13 T16 TEORI TSG TSK TSV TT1 TUC U2A U9L UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WH7 WJK WK8 YFH YLTOR Z45 Z7U Z82 Z87 Z8O Z8V Z91 ZGI ZMTXR ZOVNA ~EX AAPKM AAYXX ABBRH ABDBE ABFSG ABRTQ ACSTC ADHKG AEZWR AFDZB AFFHD AFHIU AFOHR AGQPQ AHPBZ AHWEU AIXLP ATHPR AYFIA CITATION PHGZM PHGZT PJZUB PPXIY CGR CUY CVF ECM EIF NPM 7XB 8FD 8FK FR3 K9. M7Z P64 PKEHL PQEST PQUKI PRINS 7X8 PUEGO 5PM ACNBI ADTPV AOWAS D8T DF2 ZZAVC |
| ID | FETCH-LOGICAL-c511t-d9f7b4343b0276765d5758ffbb18d633bc95459b9fd5420b4a9707a7a257e3db3 |
| IEDL.DBID | RSV |
| ISICitedReferencesCount | 8 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000545290100002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0920-3206 1573-7241 |
| IngestDate | Tue Nov 04 16:52:00 EST 2025 Tue Nov 04 01:56:38 EST 2025 Wed Oct 01 14:54:10 EDT 2025 Sat Nov 08 14:32:51 EST 2025 Mon Jul 21 06:06:09 EDT 2025 Sat Nov 29 05:51:31 EST 2025 Tue Nov 18 22:33:12 EST 2025 Fri Feb 21 02:48:34 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Keywords | Stent thrombosis CYP2C19 Intronic Translational medicine Pharmacogenomics |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c511t-d9f7b4343b0276765d5758ffbb18d633bc95459b9fd5420b4a9707a7a257e3db3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0003-3813-3469 |
| OpenAccessLink | https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-430806 |
| PMID | 32623598 |
| PQID | 2522964709 |
| PQPubID | 36270 |
| PageCount | 11 |
| ParticipantIDs | swepub_primary_oai_DiVA_org_uu_430806 pubmedcentral_primary_oai_pubmedcentral_nih_gov_7779664 proquest_miscellaneous_2420644367 proquest_journals_2522964709 pubmed_primary_32623598 crossref_citationtrail_10_1007_s10557_020_06988_w crossref_primary_10_1007_s10557_020_06988_w springer_journals_10_1007_s10557_020_06988_w |
| PublicationCentury | 2000 |
| PublicationDate | 2021-06-01 |
| PublicationDateYYYYMMDD | 2021-06-01 |
| PublicationDate_xml | – month: 06 year: 2021 text: 2021-06-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | New York |
| PublicationPlace_xml | – name: New York – name: United States – name: Dordrecht |
| PublicationTitle | Cardiovascular drugs and therapy |
| PublicationTitleAbbrev | Cardiovasc Drugs Ther |
| PublicationTitleAlternate | Cardiovasc Drugs Ther |
| PublicationYear | 2021 |
| Publisher | Springer US Springer Nature B.V |
| Publisher_xml | – name: Springer US – name: Springer Nature B.V |
| References | Mega, Close, Wiviott, Shen, Hockett, Brandt, Walker, Antman, Macias, Braunwald, Sabatine (CR5) 2009; 360 Pereira, Stewart (CR34) 2015; 90 Wrenbeck, Klesmith, Stapleton, Adeniran, Tyo, Whitehead (CR19) 2016; 13 Reese, Eeckman, Kulp, Haussler (CR24) 1997; 4 Gladding, Webster, Zeng, Farrell, Stewart, Ruygrok, Ormiston, el-Jack, Armstrong, Kay, Scott, Gunes, Dahl (CR38) 2008; 1 Doyle, Rihal, O’Sullivan, Lennon, Wiste, Bell (CR1) 2007; 116 Chaudhry, Prasad, Shirasaka, Fohner, Finkelstein, Fan, Wang, Wu, Aklillu, Sim, Thummel, Schuetz (CR47) 2015; 43 Simon, Verstuyft, Mary-Krause, Quteineh, Drouet, Meneveau (CR6) 2009; 360 Mercer, Clark, Andersen, Brunck, Haerty, Crawford, Taft, Nielsen, Dinger, Mattick (CR25) 2015; 25 Sorich, Polasek, Wiese (CR40) 2012; 108 Quax, Claassens, Soll, van der Oost (CR44) 2015; 59 Zhang (CR21) 1998; 7 Yang, Muzny, Xia, Niu, Person, Ding, Ward, Braxton, Wang, Buhay, Veeraraghavan, Hawes, Chiang, Leduc, Beuten, Zhang, He, Scull, Willis, Landsverk, Craigen, Bekheirnia, Stray-Pedersen, Liu, Wen, Alcaraz, Cui, Walkiewicz, Reid, Bainbridge, Patel, Boerwinkle, Beaudet, Lupski, Plon, Gibbs, Eng (CR35) 2014; 312 Van der Auwera, Carneiro, Hartl, Poplin, Del Angel, Levy-Moonshine (CR16) 2013; 43 McKenna, Hanna, Banks, Sivachenko, Cibulskis, Kernytsky, Garimella, Altshuler, Gabriel, Daly, DePristo (CR14) 2010; 20 Gerber, Weston, Enriquez-Sarano, Jaffe, Manemann, Jiang, Roger (CR13) 2017; 6 Sibbing, Koch, Gebhard, Schuster, Braun, Stegherr, Morath, Schömig, von Beckerath, Kastrati (CR37) 2010; 121 Wang, An, Wang, Gao, Liu, Bian, Zhu, Chen (CR42) 2011; 39 Jo, Choi (CR46) 2015; 13 DePristo, Banks, Poplin, Garimella, Maguire, Hartl (CR15) 2011; 43 Holmes, Dehmer, Kaul, Leifer, O’Gara, Stein (CR31) 2010; 56 Pereira, Rihal, So, Rosenberg, Lennon, Mathew (CR3) 2019; 12 Matreyek, Starita, Stephany, Martin, Chiasson, Gray, Kircher, Khechaduri, Dines, Hause, Bhatia, Evans, Relling, Yang, Shendure, Fowler (CR18) 2018; 50 Yeo, Burge (CR22) 2004; 11 Cayla, Hulot, O'Connor, Pathak, Scott, Gruel (CR2) 2011; 306 Gurbel, Shuldiner, Bliden, Ryan, Pakyz, Tantry (CR39) 2011; 161 Shuldiner, O'Connell, Bliden, Gandhi, Ryan, Horenstein, Damcott, Pakyz, Tantry, Gibson, Pollin, Post, Parsa, Mitchell, Faraday, Herzog, Gurbel (CR8) 2009; 302 Brown, Pereira (CR48) 2018; 8 Wallentin, James, Storey, Armstrong, Barratt, Horrow, Husted, Katus, Steg, Shah, Becker (CR9) 2010; 376 Mega, Simon, Collet, Anderson, Antman, Bliden, Cannon, Danchin, Giusti, Gurbel, Horne, Hulot, Kastrati, Montalescot, Neumann, Shen, Sibbing, Steg, Trenk, Wiviott, Sabatine (CR7) 2010; 304 Andell, James, Cannon, Cyr, Himmelmann, Husted, Keltai, Koul, Santoso, Steg, Storey, Wallentin, Erlinge (CR11) 2015; 4 Lin, Hargreaves, Li, Reiter, Wang, Mort, Cooper, Zhou, Zhang, Eadon, Dolan, Ipe, Skaar, Liu (CR27) 2019; 20 Pertea, Lin, Salzberg (CR23) 2001; 29 Scott, Sangkuhl, Stein, Hulot, Mega, Roden, Klein, Sabatine, Johnson, Shuldiner (CR36) 2013; 94 Bernard, Chouery, Putorti, Tetreault, Takanohashi, Carosso (CR4) 2011; 89 Pedersen, Nielsen, Stage, Vinholt, el Achwah, Damkier, Brosen (CR41) 2014; 41 Takahashi, Saito, Ito, Tsukada, Katono, Hosono, Maekawa, Shimada, Mano, Oda, Hirasawa, Hiratsuka (CR29) 2015; 15 Matreyek, Stephany, Fowler (CR17) 2017; 45 Blaisdell, Mohrenweiser, Jackson, Ferguson, Coulter, Chanas, Xi, Ghanayem, Goldstein (CR30) 2002; 12 Pereira, Sargent, Farkouh, Rihal (CR33) 2015; 12 Stein, Frydman (CR45) 2019; 294 Desmet, Hamroun, Lalande, Collod-Beroud, Claustres, Beroud (CR26) 2009; 37 Shapiro, Senapathy (CR20) 1987; 15 Boyle, Hong, Hariharan, Cheng, Schaub, Kasowski, Karczewski, Park, Hitz, Weng, Cherry, Snyder (CR28) 2012; 22 Pereira, Geske, Mayr, Shah, Rihal (CR32) 2016; 9 St Sauver, Grossardt, Yawn, Melton, Pankratz, Brue (CR12) 2012; 41 Olson, Ryu, Johnson, Koenig, Maschke, Morrisette, Liebow, Takahashi, Fredericksen, Sharma, Anderson, Hathcock, Carnahan, Pathak, Lindor, Beebe, Thibodeau, Cerhan (CR10) 2013; 88 Devarajan, Moon, Ho, Larson, Neavin, Moyer, Black, Bielinski, Scherer, Wang, Weinshilboum, Reid (CR43) 2019; 47 P Gladding (6988_CR38) 2008; 1 FO Desmet (6988_CR26) 2009; 37 MB Shapiro (6988_CR20) 1987; 15 G Bernard (6988_CR4) 2011; 89 MA DePristo (6988_CR15) 2011; 43 G Yeo (6988_CR22) 2004; 11 H Lin (6988_CR27) 2019; 20 D Sibbing (6988_CR37) 2010; 121 BS Jo (6988_CR46) 2015; 13 P Andell (6988_CR11) 2015; 4 NL Pereira (6988_CR32) 2016; 9 JE Olson (6988_CR10) 2013; 88 AR Shuldiner (6988_CR8) 2009; 302 M Takahashi (6988_CR29) 2015; 15 AP Boyle (6988_CR28) 2012; 22 AS Chaudhry (6988_CR47) 2015; 43 B Doyle (6988_CR1) 2007; 116 M Pertea (6988_CR23) 2001; 29 NL Pereira (6988_CR34) 2015; 90 MJ Sorich (6988_CR40) 2012; 108 TR Mercer (6988_CR25) 2015; 25 Y Yang (6988_CR35) 2014; 312 T Simon (6988_CR6) 2009; 360 JL Mega (6988_CR7) 2010; 304 S Devarajan (6988_CR43) 2019; 47 SA Brown (6988_CR48) 2018; 8 JL Mega (6988_CR5) 2009; 360 KA Matreyek (6988_CR18) 2018; 50 SA Scott (6988_CR36) 2013; 94 L Wallentin (6988_CR9) 2010; 376 KC Stein (6988_CR45) 2019; 294 A McKenna (6988_CR14) 2010; 20 DR Holmes Jr (6988_CR31) 2010; 56 H Wang (6988_CR42) 2011; 39 Y Gerber (6988_CR13) 2017; 6 JL St Sauver (6988_CR12) 2012; 41 NL Pereira (6988_CR33) 2015; 12 RS Pedersen (6988_CR41) 2014; 41 J Blaisdell (6988_CR30) 2002; 12 G Cayla (6988_CR2) 2011; 306 GA Van der Auwera (6988_CR16) 2013; 43 PA Gurbel (6988_CR39) 2011; 161 KA Matreyek (6988_CR17) 2017; 45 TE Quax (6988_CR44) 2015; 59 MQ Zhang (6988_CR21) 1998; 7 EE Wrenbeck (6988_CR19) 2016; 13 NL Pereira (6988_CR3) 2019; 12 MG Reese (6988_CR24) 1997; 4 |
| References_xml | – volume: 12 start-page: 703 issue: 9 year: 2002 end-page: 711 ident: CR30 article-title: Identification and functional characterization of new potentially defective alleles of human CYP2C19 publication-title: Pharmacogenetics. – volume: 312 start-page: 1870 issue: 18 year: 2014 end-page: 1879 ident: CR35 article-title: Molecular findings among patients referred for clinical whole-exome sequencing publication-title: Jama. – volume: 304 start-page: 1821 issue: 16 year: 2010 end-page: 1830 ident: CR7 article-title: Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis publication-title: JAMA. – volume: 89 start-page: 415 issue: 3 year: 2011 end-page: 423 ident: CR4 article-title: Mutations of POLR3A encoding a catalytic subunit of RNA polymerase Pol III cause a recessive hypomyelinating leukodystrophy publication-title: Am J Hum Genet – volume: 294 start-page: 2076 issue: 6 year: 2019 end-page: 2084 ident: CR45 article-title: The stop-and-go traffic regulating protein biogenesis: how translation kinetics controls proteostasis publication-title: J Biol Chem – volume: 13 start-page: 112 issue: 4 year: 2015 end-page: 118 ident: CR46 article-title: Introns: the functional benefits of introns in genomes publication-title: Genomics Inform – volume: 360 start-page: 354 issue: 4 year: 2009 end-page: 362 ident: CR5 article-title: Cytochrome p-450 polymorphisms and response to clopidogrel publication-title: N Engl J Med – volume: 88 start-page: 952 issue: 9 year: 2013 end-page: 962 ident: CR10 article-title: The Mayo Clinic Biobank: a building block for individualized medicine publication-title: Mayo Clin Proc – volume: 43 start-page: 11 0 1 year: 2013 end-page: 110 33 ident: CR16 article-title: From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline publication-title: Curr Protoc Bioinformatics – volume: 15 start-page: 7155 issue: 17 year: 1987 end-page: 7174 ident: CR20 article-title: RNA splice junctions of different classes of eukaryotes: sequence statistics and functional implications in gene expression publication-title: Nucleic Acids Res – volume: 41 start-page: 1614 issue: 6 year: 2012 end-page: 1624 ident: CR12 article-title: Data resource profile: the Rochester Epidemiology Project (REP) medical records-linkage system publication-title: Int J Epidemiol – volume: 25 start-page: 290 issue: 2 year: 2015 end-page: 303 ident: CR25 article-title: Genome-wide discovery of human splicing branchpoints publication-title: Genome Res – volume: 22 start-page: 1790 issue: 9 year: 2012 end-page: 1797 ident: CR28 article-title: Annotation of functional variation in personal genomes using RegulomeDB publication-title: Genome Res – volume: 90 start-page: 701 issue: 6 year: 2015 end-page: 704 ident: CR34 article-title: Clinical implementation of cardiovascular pharmacogenomics publication-title: Mayo Clin Proc – volume: 56 start-page: 321 issue: 4 year: 2010 end-page: 341 ident: CR31 article-title: ACCF/AHA clopidogrel clinical alert: approaches to the FDA “boxed warning”: a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons publication-title: J Am Coll Cardiol – volume: 8 start-page: E8 issue: 1 year: 2018 ident: CR48 article-title: Pharmacogenomic impact of CYP2C19 variation on clopidogrel therapy in precision cardiovascular medicine publication-title: J Pers Med – volume: 20 start-page: 1297 issue: 9 year: 2010 end-page: 1303 ident: CR14 article-title: The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data publication-title: Genome Res – volume: 1 start-page: 620 issue: 6 year: 2008 end-page: 627 ident: CR38 article-title: The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix response in coronary intervention) trial publication-title: JACC Cardiovasc Interv – volume: 360 start-page: 363 issue: 4 year: 2009 end-page: 375 ident: CR6 article-title: Genetic determinants of response to clopidogrel and cardiovascular events publication-title: N Engl J Med – volume: 43 start-page: 491 issue: 5 year: 2011 end-page: 498 ident: CR15 article-title: A framework for variation discovery and genotyping using next-generation DNA sequencing data publication-title: Nat Genet – volume: 94 start-page: 317 issue: 3 year: 2013 end-page: 323 ident: CR36 article-title: Clinical pharmacogenetics implementation consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update publication-title: Clin Pharmacol Ther – volume: 9 start-page: 185 issue: 2 year: 2016 end-page: 188 ident: CR32 article-title: Pharmacogenetics of clopidogrel: an unresolved issue publication-title: Circ Cardiovasc Genet – volume: 161 start-page: 598 issue: 3 year: 2011 end-page: 604 ident: CR39 article-title: The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy publication-title: Am Heart J – volume: 4 issue: 10 year: 2015 ident: CR11 article-title: Ticagrelor versus clopidogrel in patients with acute coronary syndromes and chronic obstructive pulmonary disease: an analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial publication-title: J Am Heart Assoc – volume: 20 start-page: 254 issue: 1 year: 2019 ident: CR27 article-title: RegSNPs-intron: a computational framework for predicting pathogenic impact of intronic single nucleotide variants publication-title: Genome Biol – volume: 29 start-page: 1185 issue: 5 year: 2001 end-page: 1190 ident: CR23 article-title: GeneSplicer: a new computational method for splice site prediction publication-title: Nucleic Acids Res – volume: 45 issue: 11 year: 2017 ident: CR17 article-title: A platform for functional assessment of large variant libraries in mammalian cells publication-title: Nucleic Acids Res – volume: 11 start-page: 377 issue: 2–3 year: 2004 end-page: 394 ident: CR22 article-title: Maximum entropy modeling of short sequence motifs with applications to RNA splicing signals publication-title: J Comput Biol – volume: 39 start-page: 830 issue: 5 year: 2011 end-page: 837 ident: CR42 article-title: Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4′-hydroxylation and omeprazole 5′-hydroxylation publication-title: Drug Metab Dispos – volume: 12 start-page: e007811 issue: 4 year: 2019 ident: CR3 article-title: Clopidogrel pharmacogenetics publication-title: Circ Cardiovasc Interv – volume: 47 start-page: 425 issue: 4 year: 2019 end-page: 435 ident: CR43 article-title: Pharmacogenomic next-generation DNA sequencing: lessons from the identification and functional characterization of variants of unknown significance in CYP2C9 and CYP2C19 publication-title: Drug Metab Dispos – volume: 50 start-page: 874 issue: 6 year: 2018 end-page: 882 ident: CR18 article-title: Multiplex assessment of protein variant abundance by massively parallel sequencing publication-title: Nat Genet – volume: 116 start-page: 2391 issue: 21 year: 2007 end-page: 2398 ident: CR1 article-title: Outcomes of stent thrombosis and restenosis during extended follow-up of patients treated with bare-metal coronary stents publication-title: Circulation. – volume: 7 start-page: 919 issue: 5 year: 1998 end-page: 932 ident: CR21 article-title: Statistical features of human exons and their flanking regions publication-title: Hum Mol Genet – volume: 4 start-page: 311 issue: 3 year: 1997 end-page: 323 ident: CR24 article-title: Improved splice site detection in Genie publication-title: J Comput Biol – volume: 6 issue: 10 year: 2017 ident: CR13 article-title: Contemporary risk stratification after myocardial infarction in the community: performance of scores and incremental value of soluble suppression of tumorigenicity-2 publication-title: J Am Heart Assoc – volume: 41 start-page: 870 issue: 11 year: 2014 end-page: 878 ident: CR41 article-title: CYP2C19*17 increases clopidogrel-mediated platelet inhibition but does not alter the pharmacokinetics of the active metabolite of clopidogrel publication-title: Clin Exp Pharmacol Physiol – volume: 306 start-page: 1765 issue: 16 year: 2011 end-page: 1774 ident: CR2 article-title: Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis publication-title: Jama. – volume: 302 start-page: 849 issue: 8 year: 2009 end-page: 857 ident: CR8 article-title: Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy publication-title: JAMA. – volume: 13 start-page: 928 issue: 11 year: 2016 end-page: 930 ident: CR19 article-title: Plasmid-based one-pot saturation mutagenesis publication-title: Nat Methods – volume: 12 start-page: 475 issue: 8 year: 2015 end-page: 487 ident: CR33 article-title: Genotype-based clinical trials in cardiovascular disease publication-title: Nat Rev Cardiol – volume: 108 start-page: 199 issue: 1 year: 2012 end-page: 200 ident: CR40 article-title: Systematic review and meta-analysis of the association between cytochrome P450 2C19 genotype and bleeding publication-title: Thromb Haemost – volume: 59 start-page: 149 issue: 2 year: 2015 end-page: 161 ident: CR44 article-title: Codon bias as a means to fine-tune gene expression publication-title: Mol Cell – volume: 37 issue: 9 year: 2009 ident: CR26 article-title: Human Splicing Finder: an online bioinformatics tool to predict splicing signals publication-title: Nucleic Acids Res – volume: 15 start-page: 26 issue: 1 year: 2015 end-page: 32 ident: CR29 article-title: Functional characterization of 21 CYP2C19 allelic variants for clopidogrel 2-oxidation publication-title: Pharmacogenomics J – volume: 43 start-page: 1226 issue: 8 year: 2015 end-page: 1235 ident: CR47 article-title: The CYP2C19 intron 2 branch point SNP is the ancestral polymorphism contributing to the poor metabolizer phenotype in livers with CYP2C19*35 and CYP2C19*2 alleles publication-title: Drug Metab Dispos – volume: 376 start-page: 1320 issue: 9749 year: 2010 end-page: 1328 ident: CR9 article-title: Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial publication-title: Lancet. – volume: 121 start-page: 512 issue: 4 year: 2010 end-page: 518 ident: CR37 article-title: Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement publication-title: Circulation. – volume: 8 start-page: E8 issue: 1 year: 2018 ident: 6988_CR48 publication-title: J Pers Med doi: 10.3390/jpm8010008 – volume: 94 start-page: 317 issue: 3 year: 2013 ident: 6988_CR36 publication-title: Clin Pharmacol Ther doi: 10.1038/clpt.2013.105 – volume: 12 start-page: e007811 issue: 4 year: 2019 ident: 6988_CR3 publication-title: Circ Cardiovasc Interv doi: 10.1161/CIRCINTERVENTIONS.119.007811 – volume: 25 start-page: 290 issue: 2 year: 2015 ident: 6988_CR25 publication-title: Genome Res doi: 10.1101/gr.182899.114 – volume: 41 start-page: 870 issue: 11 year: 2014 ident: 6988_CR41 publication-title: Clin Exp Pharmacol Physiol doi: 10.1111/1440-1681.12297 – volume: 43 start-page: 1226 issue: 8 year: 2015 ident: 6988_CR47 publication-title: Drug Metab Dispos doi: 10.1124/dmd.115.064428 – volume: 56 start-page: 321 issue: 4 year: 2010 ident: 6988_CR31 publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2010.05.013 – volume: 90 start-page: 701 issue: 6 year: 2015 ident: 6988_CR34 publication-title: Mayo Clin Proc doi: 10.1016/j.mayocp.2015.04.011 – volume: 43 start-page: 491 issue: 5 year: 2011 ident: 6988_CR15 publication-title: Nat Genet doi: 10.1038/ng.806 – volume: 88 start-page: 952 issue: 9 year: 2013 ident: 6988_CR10 publication-title: Mayo Clin Proc doi: 10.1016/j.mayocp.2013.06.006 – volume: 43 start-page: 11 0 1 year: 2013 ident: 6988_CR16 publication-title: Curr Protoc Bioinformatics doi: 10.1002/0471250953.bi1110s43 – volume: 360 start-page: 354 issue: 4 year: 2009 ident: 6988_CR5 publication-title: N Engl J Med doi: 10.1056/NEJMoa0809171 – volume: 12 start-page: 475 issue: 8 year: 2015 ident: 6988_CR33 publication-title: Nat Rev Cardiol doi: 10.1038/nrcardio.2015.64 – volume: 11 start-page: 377 issue: 2–3 year: 2004 ident: 6988_CR22 publication-title: J Comput Biol doi: 10.1089/1066527041410418 – volume: 116 start-page: 2391 issue: 21 year: 2007 ident: 6988_CR1 publication-title: Circulation. doi: 10.1161/CIRCULATIONAHA.107.707331 – volume: 306 start-page: 1765 issue: 16 year: 2011 ident: 6988_CR2 publication-title: Jama. doi: 10.1001/jama.2011.1529 – volume: 376 start-page: 1320 issue: 9749 year: 2010 ident: 6988_CR9 publication-title: Lancet. doi: 10.1016/S0140-6736(10)61274-3 – volume: 20 start-page: 254 issue: 1 year: 2019 ident: 6988_CR27 publication-title: Genome Biol doi: 10.1186/s13059-019-1847-4 – volume: 1 start-page: 620 issue: 6 year: 2008 ident: 6988_CR38 publication-title: JACC Cardiovasc Interv doi: 10.1016/j.jcin.2008.09.008 – volume: 59 start-page: 149 issue: 2 year: 2015 ident: 6988_CR44 publication-title: Mol Cell doi: 10.1016/j.molcel.2015.05.035 – volume: 47 start-page: 425 issue: 4 year: 2019 ident: 6988_CR43 publication-title: Drug Metab Dispos doi: 10.1124/dmd.118.084269 – volume: 13 start-page: 112 issue: 4 year: 2015 ident: 6988_CR46 publication-title: Genomics Inform doi: 10.5808/GI.2015.13.4.112 – volume: 50 start-page: 874 issue: 6 year: 2018 ident: 6988_CR18 publication-title: Nat Genet doi: 10.1038/s41588-018-0122-z – volume: 29 start-page: 1185 issue: 5 year: 2001 ident: 6988_CR23 publication-title: Nucleic Acids Res doi: 10.1093/nar/29.5.1185 – volume: 6 issue: 10 year: 2017 ident: 6988_CR13 publication-title: J Am Heart Assoc doi: 10.1161/JAHA.117.005958 – volume: 121 start-page: 512 issue: 4 year: 2010 ident: 6988_CR37 publication-title: Circulation. doi: 10.1161/CIRCULATIONAHA.109.885194 – volume: 15 start-page: 7155 issue: 17 year: 1987 ident: 6988_CR20 publication-title: Nucleic Acids Res doi: 10.1093/nar/15.17.7155 – volume: 89 start-page: 415 issue: 3 year: 2011 ident: 6988_CR4 publication-title: Am J Hum Genet doi: 10.1016/j.ajhg.2011.07.014 – volume: 302 start-page: 849 issue: 8 year: 2009 ident: 6988_CR8 publication-title: JAMA. doi: 10.1001/jama.2009.1232 – volume: 37 issue: 9 year: 2009 ident: 6988_CR26 publication-title: Nucleic Acids Res doi: 10.1093/nar/gkp215 – volume: 294 start-page: 2076 issue: 6 year: 2019 ident: 6988_CR45 publication-title: J Biol Chem doi: 10.1074/jbc.REV118.002814 – volume: 360 start-page: 363 issue: 4 year: 2009 ident: 6988_CR6 publication-title: N Engl J Med doi: 10.1056/NEJMoa0808227 – volume: 15 start-page: 26 issue: 1 year: 2015 ident: 6988_CR29 publication-title: Pharmacogenomics J doi: 10.1038/tpj.2014.30 – volume: 45 issue: 11 year: 2017 ident: 6988_CR17 publication-title: Nucleic Acids Res doi: 10.1093/nar/gkx183 – volume: 4 start-page: 311 issue: 3 year: 1997 ident: 6988_CR24 publication-title: J Comput Biol doi: 10.1089/cmb.1997.4.311 – volume: 312 start-page: 1870 issue: 18 year: 2014 ident: 6988_CR35 publication-title: Jama. doi: 10.1001/jama.2014.14601 – volume: 108 start-page: 199 issue: 1 year: 2012 ident: 6988_CR40 publication-title: Thromb Haemost – volume: 20 start-page: 1297 issue: 9 year: 2010 ident: 6988_CR14 publication-title: Genome Res doi: 10.1101/gr.107524.110 – volume: 22 start-page: 1790 issue: 9 year: 2012 ident: 6988_CR28 publication-title: Genome Res doi: 10.1101/gr.137323.112 – volume: 7 start-page: 919 issue: 5 year: 1998 ident: 6988_CR21 publication-title: Hum Mol Genet doi: 10.1093/hmg/7.5.919 – volume: 304 start-page: 1821 issue: 16 year: 2010 ident: 6988_CR7 publication-title: JAMA. doi: 10.1001/jama.2010.1543 – volume: 41 start-page: 1614 issue: 6 year: 2012 ident: 6988_CR12 publication-title: Int J Epidemiol doi: 10.1093/ije/dys195 – volume: 12 start-page: 703 issue: 9 year: 2002 ident: 6988_CR30 publication-title: Pharmacogenetics. doi: 10.1097/00008571-200212000-00004 – volume: 4 issue: 10 year: 2015 ident: 6988_CR11 publication-title: J Am Heart Assoc doi: 10.1161/JAHA.115.002490 – volume: 13 start-page: 928 issue: 11 year: 2016 ident: 6988_CR19 publication-title: Nat Methods doi: 10.1038/nmeth.4029 – volume: 161 start-page: 598 issue: 3 year: 2011 ident: 6988_CR39 publication-title: Am Heart J doi: 10.1016/j.ahj.2010.12.011 – volume: 39 start-page: 830 issue: 5 year: 2011 ident: 6988_CR42 publication-title: Drug Metab Dispos doi: 10.1124/dmd.110.037549 – volume: 9 start-page: 185 issue: 2 year: 2016 ident: 6988_CR32 publication-title: Circ Cardiovasc Genet doi: 10.1161/CIRCGENETICS.115.001318 |
| SSID | ssj0007998 |
| Score | 2.3232157 |
| Snippet | Purpose
Describe
CYP2C19
sequencing results in the largest series of clopidogrel-treated cases with stent thrombosis (ST), the closest clinical phenotype to... Describe CYP2C19 sequencing results in the largest series of clopidogrel-treated cases with stent thrombosis (ST), the closest clinical phenotype to... PurposeDescribe CYP2C19 sequencing results in the largest series of clopidogrel-treated cases with stent thrombosis (ST), the closest clinical phenotype to... PURPOSE: Describe CYP2C19 sequencing results in the largest series of clopidogrel-treated cases with stent thrombosis (ST), the closest clinical phenotype to... |
| SourceID | swepub pubmedcentral proquest pubmed crossref springer |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 549 |
| SubjectTerms | Aged Alleles Annotations Cardiology Clopidogrel Clopidogrel - administration & dosage Clopidogrel - pharmacokinetics CYP2C19 Cytochrome P-450 CYP2C19 - genetics Diabetes mellitus Drug Resistance - genetics Evaluation Exome - genetics Female Genetic diversity Heterozygotes Humans Impact resistance Implants Intronic Introns Male Medicine Medicine & Public Health Middle Aged Next-generation sequencing Original Article Pharmacogenomics Phenotypes Platelet aggregation Platelet Aggregation Inhibitors - administration & dosage Platelet Aggregation Inhibitors - pharmacokinetics Protein expression Proteins Stent thrombosis Stents Thrombosis Thrombosis - prevention & control Translational medicine |
| SummonAdditionalLinks | – databaseName: ProQuest Central dbid: BENPR link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB7BFiEuPMorUJCRoBc2IomTOOaCytIKJFitoKBystZJ3EZqk5LsUvXfM5N4E5ZKe-Fsxw_N2PnGM_MNwMvI-FEqYukazjM3RIDh6igSbmr8xIQ-UcW27PqfxXSaHB3JmX1wa2xY5epObC_qrErpjfxNgECBsiY9-e78l0tVo8i7aktoXIctYioLR7D1fn86-9rfxUK21XA9SXnCgRfbtBmbPEeLIvPJiyXqy8X6r-kK3rwaNtn7Tv_hGW3_TQd3_ndXd-G2RaVsr1Oje3AtL7fh5hfrd9-G3VnHcH05ZodDwlYzZrtsNnBfX96HkylZ0h2XNYmcfetCtXH9rDJs8nMWTHzJCmxAsL7A0erqTFdN0bxln_4KbmeIpdmEsrmy6rjOT_tpiFP2DKd-AN8P9g8nH11bzMFNEdMt3EwaoSmNVaMhHIs4yhAoJsZo7SdZzLlOJYI5qaXJojDwdDiXwhNzMcc7JeeZ5g9hVFZl_hhYiiNxrUWQGR4aKWSUomGLyI4nXh57xgF_JUeVWqZzKrhxqgaOZpK9QtmrVvbqwoHX_TfnHc_Hxt47K3Eqe-YbNcjSgRd9M55WcsHMy7xaYh_cGiJQHgsHHnXa1E-HQDogPkUHxJqe9R2ICXy9pSxOWkZwIQSaraED45VGDsvatItXndauzfCh-LGnqvpYLZcq5GhQxE827_Yp3Aoo0Kd9mtqB0aJe5s_gRvp7UTT1c3si_wD-qT02 priority: 102 providerName: ProQuest |
| Title | Next-Generation Sequencing of CYP2C19 in Stent Thrombosis: Implications for Clopidogrel Pharmacogenomics |
| URI | https://link.springer.com/article/10.1007/s10557-020-06988-w https://www.ncbi.nlm.nih.gov/pubmed/32623598 https://www.proquest.com/docview/2522964709 https://www.proquest.com/docview/2420644367 https://pubmed.ncbi.nlm.nih.gov/PMC7779664 https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-430806 |
| Volume | 35 |
| WOSCitedRecordID | wos000545290100002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAVX databaseName: SpringerLINK Contemporary 1997-Present customDbUrl: eissn: 1573-7241 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0007998 issn: 0920-3206 databaseCode: RSV dateStart: 19970101 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fb9MwED6xDSFeYAwGga0yEuyFRkrixI5527pNIEEVbWMqT1adxCzSlqCmZdp_z9n50ZWhSfCSFzvn2D7b3-XuPgO8i7QfpZwJV1OauSECDFdFEXdT7cc69A1VrGXX_8LH43gyEUmbFFZ30e6dS9Lu1LeS3YwQY-54TOD8Xq_BBh53sVmOJ6fn_f7Lhb0B1xMmNzjwWJsq83cZq8fRHYx5N1Sy95f-wS1qz6Pjp__Xk0140uJPst8ozDN4kJdb8Ohr62Hfgr2k4bK-GZKzZWpWPSR7JFmyXN88h4uxsZkb1mozueS0CcrGDyGVJqPvSTDyBSmwAGH5HKXNqitV1UX9kXy-FcZOEDWTkcnbyiq0_S_7Zgx77BU2_QK-HR-djT657bUNborobe5mQnNlElYVmryMsyhDSBhrrZQfZ4xSlQqEbUIJnUVh4KlwKrjHp3yKu0dOM0W3Yb2syvwVkBQlUaV4kGkaasFFlKIJixiOxl7OPO2A382eTFtOc3O1xqVcsjGbsZY41tKOtbx24EP_zs-G0ePe2judUsh2ddcyQNBqMng94cDbvhjXpXG2TMu8WmAd7BpiTcq4Ay8bHeqbQ8gcGOZEB_iKdvUVDOf3aklZXFjub845GqihA8NOtZafdV8v3je6utLCYXG-L6vZD7lYyJCi6cBe_5vYN_A4MCE-9qfUDqzPZ4t8Fx6mv-ZFPRvAGp9w-4wHsHFwNE5OBnal_gYtwjYp |
| linkProvider | Springer Nature |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1db9MwFL0aAzFe-BgMAgOMxPZCI5I4iWskhKaOadW6qhIFlSdTJ_FWaWtG01L1T_EbuTdfpUzq2x54tmPHzvHNPfa9xwBvA-MGkQilbTiPbR8dDFsHgbAj4zaN75JUbK6u3xHdbnMwkL0N-F3lwlBYZWUTc0MdpxHtkb_30FGgrElHfrr6adOtUXS6Wl2hUcDiJFnMkbJlH9uH-H33PO_oc791bJe3CtgROhdTO5ZGaMqn1MjIQhEGMXosTWO0dptxyLmOJHoVUksTB77naH8ohSOGYojgTnisObZ7C26jHRcUQiYGNcFzhMzv3nUkZSV7Tlgm6ZSpejQFRNacUCI656s_wmve7fUgzfqk9h9V0_xPePTgf5vDh3C_9LnZQbFIHsFGMt6Gu6dlVME27PcK_e5Fg_WX6WhZg-2z3lLZe_EYzru0T1AodROg2ZciEB3ni6WGtb73vJYr2QgLkIpMsbVJeqnTbJR9YO2_QvcZMgXWoly1OD2bJBd1N6SYe4ldP4GvNzIhO7A5TsfJM2ARtsS1Fl5suG-kkEGEtB39Vt50ktAxFrgVblRU6rjTdSIXaqlATVhTiDWVY03NLXhXP3NVqJisrb1bwUeVFi1TS-xY8KYuRltEB0zDcZLOsA4ODf1rHgoLnhborbtDmuCRWqQFYgXXdQXSOV8tGY_Oc71zIQSSct-CRrUClq-1bhR7xSpZ6eFw9O1ApZMzNZspnyNdCp-vH-1r2Drun3ZUp909eQH3PAppyjfhdmFzOpklL-FO9Gs6yiavclvA4MdNL5w_7nqXiQ |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3db9MwED-NDk174WPACAwwEtsLjZbESVwjITTaVVQbVQQbGk-mTuKt0taMpKXqv8ZfxzmflEl92wPPdu3a-d35zr77HcAbT9leyHxuKkoj00UDw5Sex8xQ2R3l2poqNmfXP2bDYefsjAdr8LvKhdFhlZVOzBV1lIT6jnzfQUNBZ01afF-VYRFBr__h-qepK0jpl9aqnEYBkaN4MUf3LXs_6OG33nWc_uFJ95NZVhgwQzQ0pmbEFZM6t1Kid-Yz34vQeukoJaXdiXxKZcjRwuCSq8hzHUu6I84sNmIjBHpMI0lx3DuwztDI8Fqw_vFwGHypzwHG80q8Ftc5yo7llyk7ZeKe3hDtulk-R6zOl4_FG7buzZDN-t32H47T_Fzs3_-fd_QB3CutcXJQiM9DWIsnW7DxuYw32IK9oGD2XrTJSZOolrXJHgkazu_FI7gY6huEgsNbQ518LULUce9Iokj3e-B0bU7G2IBOyhRHS5MrmWTj7B0Z_BXUT9CHIF2dxRYl52l8WU-juXSvcOrHcHorG_IEWpNkEj8FEuJIVErmRIq6ijPuhejQo0VLO1bsW8oAu8KQCEuGd11o5FI03NQadwJxJ3LcibkBb-vfXBf8Jit771RQEqWuy0SDIwNe182opfTT02gSJzPsg0tDy5v6zIDtAsn1dOhAOJpH0gC2hPG6g2ZAX26ZjC9yJnTGGLrrrgHtShqav7VqFbuFxCzN0Bt_OxBJei5mM-FSdKT8Z6tX-wo2UF7E8WB49Bw2HR3rlN_O7UBrms7iF3A3_DUdZ-nLUjEQ-HHbkvMHIoqhqQ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Next-Generation+Sequencing+of+CYP2C19+in+Stent+Thrombosis%3A+Implications+for+Clopidogrel+Pharmacogenomics&rft.jtitle=Cardiovascular+drugs+and+therapy&rft.au=Morales-Rosado%2C+Joel+A&rft.au=Goel%2C+Kashish&rft.au=Zhang%2C+Lingxin&rft.au=%C3%85kerblom%2C+Axel&rft.date=2021-06-01&rft.issn=1573-7241&rft.eissn=1573-7241&rft.volume=35&rft.issue=3&rft.spage=549&rft_id=info:doi/10.1007%2Fs10557-020-06988-w&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0920-3206&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0920-3206&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0920-3206&client=summon |